U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H21FN6O
Molecular Weight 344.3873
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIVAVOTINIB

SMILES

Cn1cc(cn1)-c2c3c(CN=C3O)c(c(N[C@]4([H])CCCC[C@]4([H])N)n2)F

InChI

InChIKey=MJHOMTRKVMKCNE-NWDGAFQWSA-N
InChI=1S/C17H21FN6O/c1-24-8-9(6-21-24)15-13-10(7-20-17(13)25)14(18)16(23-15)22-12-5-3-2-4-11(12)19/h6,8,11-12H,2-5,7,19H2,1H3,(H,20,25)(H,22,23)/t11-,12+/m0/s1

HIDE SMILES / InChI

Molecular Formula C17H21FN6O
Molecular Weight 344.3873
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

TAK-659 is an investigational, reversible, and potent dual inhibitor of SYK and FLT-3 kinases. TAK-659 inhibited the pro-survival, proliferative, chemoresistant, and activation effects promoted by the microenvironment. Combination of TAK-659 with other BCR inhibitors showed a synergistic effect in inducing apoptosis. Combination of TAK-659 and ibrutinib induced significantly higher cytotoxicity toward CLL cells. TAK-659 suppressed splenomegaly and tumor development in an LMP2A/Myc mouse model in nanomolar concentrations. In addition, TAK-659 also blocked metastasis of tumor cells into bone marrow. A phase Ib/II study of TAK-659 is underway in patients with relapsed or refractory acute myelogenous leukemia

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P43405
Gene ID: 6850.0
Gene Symbol: SYK
Target Organism: Homo sapiens (Human)
3.2 nM [IC50]
PubMed

PubMed

TitleDatePubMed
Syk inhibitors in clinical development for hematological malignancies.
2017 Jul 28

Sample Use Guides

During the phase Ib dose escalation study, adult pts with R/R AML received oral TAK-659 daily at doses of 60, 100, 120, and 160 mg.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Jun 26 08:10:46 UTC 2021
Edited
by admin
on Sat Jun 26 08:10:46 UTC 2021
Record UNII
8QR88H79VX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MIVAVOTINIB
INN   USAN  
Official Name English
MIVAVOTINIB [WHO-DD]
Common Name English
TAK-659F
Code English
TAK-659 FREE BASE
Code English
MIVAVOTINIB [USAN]
Common Name English
MIVAVOTINIB [INN]
Common Name English
3H-PYRROLO(3,4-C)PYRIDIN-3-ONE, 6-(((1R,2S)-2-AMINOCYCLOHEXYL)AMINO)-7-FLUORO-1,2-DIHYDRO-4-(1-METHYL-1H-PYRAZOL-4-YL)-
Systematic Name English
6-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)-7-FLUORO-4-(1-METHYL-1H-PYRAZOL-4-YL)-1H-PYRROLO(3,4-C)PYRIDIN-3(2H)-ONE
Systematic Name English
Code System Code Type Description
FDA UNII
8QR88H79VX
Created by admin on Sat Jun 26 08:10:46 UTC 2021 , Edited by admin on Sat Jun 26 08:10:46 UTC 2021
PRIMARY
PUBCHEM
53252276
Created by admin on Sat Jun 26 08:10:46 UTC 2021 , Edited by admin on Sat Jun 26 08:10:46 UTC 2021
PRIMARY
CAS
1312691-33-0
Created by admin on Sat Jun 26 08:10:46 UTC 2021 , Edited by admin on Sat Jun 26 08:10:46 UTC 2021
PRIMARY
INN
10836
Created by admin on Sat Jun 26 08:10:46 UTC 2021 , Edited by admin on Sat Jun 26 08:10:46 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Assessed by Invitrogen/Life Technologies using the Z’-LYTE assay format
REVERSIBLE
IC50
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Caliper electrophoretic mobility shift kinase assay
REVERSIBLE
IC50
Related Record Type Details
ACTIVE MOIETY